Author's reply

Sir—O M Kon and D S Robinson refer to a meta-analysis on methotrexate treatment. This study showed that methotrexate treatment resulted in fewer steroid-sparing effects than other immunosuppressive agents. However, Marin concluded that longitudinal studies of both steroid and methotrexate were necessary before methotrexate could be recommended for routine clinical use. I do not disagree with Kon and Robinson that the alternative anti-inflammatory agents can be considered in certain patients with severe steroid toxicity. In all patients with severe asthma A B Kay and N C Barnes draw attention to their study showing the steroid-sparing effects of cyclosporin in steroid-dependent asthma. The study referred to in the table was their earlier investigation showing improvement in lung function with cyclosporin. The aim of this study was to comment on steroid-sparing effects only, and this fact was signalled in the original title for the figure. Unfortunately, “steroid-sparing” was omitted from the title in the published version.

S H Lock and co-workers' study shows variable steroid-sparing effects in people with chronic asthma. The difference between the mean daily use of prednisolone in the cyclosporin and placebo treated groups was modest (4.4 mg). Although greater reductions in steroid use were achieved during the later weeks of the study, it was not clear that these reductions could be maintained with continued use. Whether the reduction in steroid toxicity could justify the additional toxicity incurred with cyclosporin is conjectural. Although the renal impairment incurred with cyclosporin was said to be reversible, longer treatment with low-dose cyclosporin has resulted in permanent morphological renal damage. Aside from issues of drug toxicity, the use of cyclosporin does not lend itself to routine management. Careful monitoring is essential and rigorous attempts at steroid reduction are necessary to achieve the steroid-sparing effects cited.

D Arthur Banner
Department of Veterans Affairs, Medical Center, Manchester, NH 03104, USA

---

Malarone-donation programme in Africa

Sir—We welcome the addition of atovaquone to the short list of antimalarial drugs that are effective against multidrug-resistant falciparum malaria. However, the possible negative effects of Glaxo's planned donation programme of Malarone (atovaquone-proguanil combination) are a cause for concern. We agree with Peter Bloland and colleagues (Nov 29, p 1624) that the disadvantages associated with this introduction of this drug in Africa may outweigh potential benefits.

Do African countries really need one million “free” doses of Malarone each year? Despite the spread of drug resistance, chloroquine is still a useful drug in everyday life. Currently available second-line and third-line drugs are also cost-effective for the management of uncomplicated (amodiaquine, sulfadoxine-pyrimethamine) and severe and complicated (quinine) malaria. Other new antimalarial drugs (mefloquine, halofantrine, artesunate, atezolane) are not only expensive but do not have any clear indication for the treatment of indigenous patients, since multidrug resistance has not been fully documented in Africa. Why then add another new drug when there is no well-defined role for Malarone in Africa today?

Rare but severe and potentially fatal adverse effects of mefloquine and halofantrine have been documented in Europe, North America, and Thailand, countries where the health-care system allows pharmacovigilance. If Malarone is distributed in Africa, a country where health-care facilities, follow-up of patients, and compliance are generally poor, who would guarantee the continued safety of the drug?

Furthermore, crossresistance between sulfadoxine-pyrimethamine and Malarone is possible. Our studies show that in-vitro responses of Plasmodium falciparum isolates to two dihydrofolate-reductase inhibitors—pyrimethamine and cycloguanil (a biologically active metabolite of proguanil)—are highly correlated, which suggests a real potential for in-vivo crossresistance if the proportion and degree of resistance to one of these two drugs increase in Africa. In addition, the same single-point mutation within the dihydrofolate reductase gene has been associated with resistance to pyrimethamine and cycloguanil. The epidemiology of drug resistance in southeast Asia strongly suggests that the widespread use of pyrimethamine led to the development of resistance to pyrimethamine and cycloguanil.

Thus, if Malarone is widely used in Africa, its prophylactic component will exert drug pressure and may select pyrimethamine-resistant mutants, leading to the spread of resistance to sulfadoxine-pyrimethamine. Such a scenario will be disastrous since sulfadoxine-pyrimethamine has so far been, and still is, a reliable, cheap, and safe alternative to chloroquine throughout Africa.

Another potential difficulty is the selection of correctly diagnosed, eligible patients. It is not clear who would benefit from free medication.

Further, the possible negative effects of Glaxo's planned donation programme of Malarone (atovaquone-proguanil combination) are a cause for concern. We agree with Peter Bloland and colleagues (Nov 29, p 1624) that the disadvantages associated with this introduction of this drug in Africa may outweigh potential benefits.

3 Basco WJ, Eldin de Phicoulas J, Wilson CM, De La SS, Lauermann J. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and...

Poliomyelitis vaccination in an infant with hypogammaglobulinaemia

Sir—W L Yeung and colleagues (Nov 29, p 1594) report an unusual case of a 6-month-old infant who presented with high fever, convulsions, and encephalitis. They believe that the poliovirus isolated in the infant's brain after death was the cause of the encephalitis, because of the underlying hypogammaglobulinaemia.

A boy aged 5 months was transferred from an Albanian hospital to our department in March, 1996. He had had cephalospinor, aminoglycoside, and prednisolone for respiratory infection without improvement. On admission he had cyanosis and tachypnoea (90 breaths per min) with bilateral pneumothorax, but no other clinical abnormalities. He was put on mechanical respiratory support for 2 weeks. Tracheal culture revealed coagulase-negative staphylococcus sensitive to vancomycin and he was given cephalospinor and vancomycin. Differential white cell count, C-reactive protein, and chest radiography suggested an infection in the lungs. B and T lymphocytes were normal, but immunoglobulin concentrations were abnormally low for his age (IgG 0.066 g/L, IgM 0.056 g/L, IgA 0.066 g/L, and CD3/CD4 lymphocyte ratio 2-9 [normal 1.2–1.61]) and the child was given all the regular vaccines. The patient was examined clinically in January, 1998, and his development and growth was normal.

From this report is seems that if hypogammaglobulinaemia is transient, it is probably secondary to infection.

*S Andronikou,
A Stamopoulou-Mavridou, M Pontikaki,
P D Lapatsanis
Child Health Department, University of Ioannina, Ioannina 45100, Greece

Danaparoid sodium in diabetic retinopathy

Sir—The report by Johan W van der Pijl and co-workers (Dec 13, p 1743) suggests that the heparin-like molecules and glycosaminoglycans (GAGs) may be systemically adjuvant for the treatment of diabetic retinopathy. This observation is also important because it supports the optical safety of GAGs therapy.

Experimental and clinical reports have shown that GAGs improve microalbuminuria and diabetic nephropathy. However, one major concern has been the risk of their anticoagulant activity, particularly in patients with retinal neangiogenesis, due to the fragility of new vessels. Although this probably represented excessive caution with regard to the doses used, sufficient only in inhibiting factor X, van der Pijl shows the therapy to be safe.

This report is also important because it indirectly gives insight into the pathogenesis of diabetic microangiopathy. In diabetic retinopathy (both the proliferative form and maculopathy), overexpressed vascular endothelial growth factor (VEGF) has a pivotal role,6 and various approaches have been devised for blocking its action.7 In physiological conditions, some VEGF isoforms are sequestered, and modulated by extracellular-matrix-sulfated glycosaminoglycans. Alterations of the sulphation of glycosaminoglycans in diabetes are well known, and exogenous GAGs revert these disorders. Thus, the effect of danaparoid on hard exudates could be related to the modulation of sequestered VEGF in the retina.

Finally, that a drug such as danaparoid works concurrently on diabetic retinopathy and nephropathy lends support to the idea that these have common pathogenic steps and genetic background.

Giovanni Gambaro
Institute of Internal Medicine, Division of Nephrology, University Hospital, University of Padua, 35128 Padua, Italy


Diabetic ketoacidosis and compliance

Sir—Andrew Morris and colleagues (Nov 22, p 1505)1 find evidence of poor compliance with insulin-therapy in young patients with insulin-dependent diabetes mellitus (IDDM). They suggest that lack of adherence to insulin treatment was the major factor contributing to long-term poor glycaemic control and to diabetic ketoacidosis (DKA) in these young patients. We have reported a relation between level of education and the severity of diabetic ketoacidosis, with more severe acidosis seen among patients with less advanced education.2

We have conducted an 11-year retrospective case-note review of all episodes of diabetic ketoacidosis admitted to our department between January, 1987, and December, 1997. Only patients older than 15 years were included because younger patients were admitted to the department of paediatrics. We defined diabetic ketoacidosis as newly diagnosed or
EDITORIAL
609 Control of health claims in foods

COMMENTARY
610 Assessment of risk of cancer after renal transplantation
C G Newstead
611 Vaccine adverse events: causal or coincidental?
R T Chen, F DeStefano
612 How the colon begets gallstones
T S Low-Beer
613 Sublingual immunotherapy for allergic respiratory disease
P G Holt and others

ARTICLES
615 Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting
M S Lauer and others
622 Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two ciclosporin regimens
J Dantal and others
629 Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis
G Passalacqua and others
633 Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea
J K Shim and others

EARLY REPORT
637 Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive-developmental disorder in children
A J Wakefield and others

CASE REPORT
642 Pubic pain after a marathon
L Baril and others

RESEARCH LETTERS
643 Increase in US medication-error deaths between 1993 and 1993
D P Phillips and others
644 Gemcitabine-associated autonomic neuropathy
A J Dormann and others
644 Experimental evidence to support ELITE
L C Rump and others
645 Glutathione: in sickness and in health
S L Nuttall and others
646 Absence of measles-virus genome in inflammatory bowel disease
M A Afzal and others
647 Neonatal blood: a source of haematopoietic stem cells for transplantation?
K Li and others
648 Icteric toxic hepatitis associated with rifecol
L I Castellis and others
649 House-dust mite antigen on skin and sheets
G Riley and others
650 Outcome of raising blood pressure in patients with penetrating trunk wounds
N Shah and others
650 House-dust mite antigen on skin and sheets
G Riley and others
650 Saddleback fever due to human granulocytic ehrlichiosis
H W Horowitz and others
650 Emergency use of cellular (mobile) telephones
S Chapman, W N Schofield

NEWS
Science & medicine
651 UK patients with hip implants to be reviewed
Short-course AZT halves HIV-1 perinatal transmission
652 Multiple therapies for cervical cancer
Cancer survivors as parents
Schizophrenia complexities yield
653 Antipodean apoptosis
Fulminant hepatitis B in Italy

Feature
654 Sounding out the brain with transcranial doppler

Dispatches
655 Brazil's health surveillance
Spain's drug-spending crackdown
Policy & people
656 Abuse in Romania's hospitals
France reduces drug bill
Illicit drug use in Switzerland
657 Depleted uranium in Iraq
US anthrax-vaccine production
Japan challenged on germ warfare
658 Aid for Afghanistan
Biological-weapon threat in Middle East

SEMINAR
659 Familial Mediterranean fever
E Ben-Chetrit, M Levy

WORLD HEALTH
665 The World Bank and global cooperation in health: the case in Bangladesh
K Buse, C Gwin

HYPOTHESIS
670 Membranous nephropathy: an IgG4-mediated disease
D B G Oliveira

Contents list continues inside